FDA OKs Merck GARDASIL 9 to Prevent HPV-Related Head and Neck Cancers

Merck & Company (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for GARDASIL 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The trial is currently underway.
https://www.biospace.com/article/releases/fda-approves-merck-s-gardasil-9-for-the-prevention-of-certain-hpv-related-head-and-neck-cancers/